Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.72 |
| ▸ | SYK | P43405 | 2/20 | 0.72 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.72 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.72 |
| ▸ | FES | P07332 | 1/20 | 0.58 |
| ▸ | FER | P16591 | 1/20 | 0.58 |
| ▸ | FRK | P42685 | 1/20 | 0.58 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.58 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.58 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30273129 | 1.00 | TYK2 (0.72) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL3560513 | 0.90 | PIK3CA (0.66) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL11929833 | 0.86 | TYK2 (0.72) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL3110596 | 0.86 | TYK2 (0.75) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL12634088 | 0.85 | TYK2 (0.70) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL1877075 | 0.84 | TYK2 (0.68) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL31025329 | 0.84 | TYK2 (1.00) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL1616481 | 0.84 | TYK2 (1.00) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL30273130 | 0.84 | TYK2 (1.00) | TYK2SYKIRAK4BRSK1FES | |
| SCHEMBL1617732 | 0.83 | TYK2 (0.61) | TYK2SYKIRAK4BRSK1FES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113683596-B | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2023-02-10 | — | — | CN | claimed |
| CN-113683596-A | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2021-11-23 | — | — | CN | claimed |
| CN-113683596-B | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2023-02-10 | — | — | CN | disclosed |
| CN-113683596-A | Pyrimidine tankyrase 2 inhibitor and preparation method and application thereof | 上海应用技术大学 | 2021-11-23 | — | — | CN | disclosed |
| US-20180271873-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2018-09-27 | — | — | US | disclosed |
| WO-2016161176-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161176-A1 | METHODS FOR TREATING VIRAL INFECTIONS | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-06 | — | — | WO | disclosed |
| EP-1458687-B1 | PYRIMIDINE COMPOUNDS AS INTERLEUKIN-12 (IL-12) INHIBITORS | SYNTA PHARMACEUTICALS CORP (US) | 2012-01-11 | — | — | EP | disclosed |
| US-7923557-B2 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923557-B2 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923557-B2 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-12 | — | — | US | disclosed |
| US-7470681-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20060122209-A1 | Process for preparing trisubstituted pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-06-08 | — | — | US | disclosed |
| WO-2006053112-A1 | PROCESS FOR PREPARING TRISUBSTITUTED PYRIMIDINE COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060030560-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-02-09 | — | — | US | disclosed |
| US-6958332-B2 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2005-10-25 | — | — | US | disclosed |
| US-20040053937-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2004-03-18 | — | — | US | disclosed |
| US-6660733-B2 | Induce immunology response | SYNTA PHARMACEUTICALS CORP. | 2003-12-09 | — | — | US | disclosed |
| US-20030114446-A1 | Pyrimidine compounds | SYNTA PHARMACEUTICALS CORP. | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122209-A1 | Process for preparing trisubstituted pyrimidine compounds | TYMS, NUDT1, TYMP | TYK2 1701/4885SYK 1920/4885IRAK4 3254/4885 |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | TYK2 2409/4885SYK 3624/4885IRAK4 2390/4885 |
| US-20180271873-A1 | METHODS FOR TREATING VIRAL INFECTIONS | HAVCR2, CCL11, EIF2AK2 | TYK2 3663/4885SYK 2919/4885IRAK4 736/4885 |
| US-20040053937-A1 | Pyrimidine compounds | CCNO, CNR1, CBR1 | TYK2 1328/4885SYK 2584/4885IRAK4 2350/4885 |
| US-20030114446-A1 | Pyrimidine compounds | CCNO, CNR1, CBR1 | TYK2 1224/4885SYK 2693/4885IRAK4 2272/4885 |
| US-20060030560-A1 | Pyrimidine compounds | CCNO, CCNC, TYMS | TYK2 383/4885SYK 309/4885IRAK4 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.